HIGHLIGHTS
SUMMARY
Cancers are known as metabolic diseases that are characterized by immoderate proliferation. Large clinical cohort studies are ideal for obtaining reliable oncometabolites as potential cofounding factors or individual differences are better controlled than small studies. An alternative to large cohort studies is integrating the invaluable existing data from small metabolomics studies. Due to different experimental conditions applied in the individual laboratory (e_g, instrument, analytical method, and pretreatment of samples ), metabolomics studies of identical diseases could lead to distinct results, making it difficult to obtain comparable information from these smallscale studies of various sources. There . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.